PAVmed Inc
PAVM0.527USD
+0.001+0.25%
Trading geöffnet （ET）Kurse um 15 Minuten verzögert
8.83MMarktkapitalisierung
0.12KGV TTM
mehr Informationen über PAVmed Inc Unternehmen
PAVmed Inc. is a multi-product, commercial-stage medical technology company. The Company operates through three lines of business: Medical Devices, Diagnostics, and Digital Health. Its subsidiary includes Lucid Diagnostics Inc., which is a commercial-stage cancer prevention medical diagnostics company that markets the EsoGuard Esophageal DNA Test and EsoCheck Esophageal Cell Collection Device for early detection of esophageal precancer to prevent esophageal cancer deaths. EsoCheck is a noninvasive swallowable balloon capsule catheter device capable of sampling surface esophageal cells. EsoGuard is a bisulfite-converted next-generation sequencing (NGS) DNA assay performed on surface esophageal cells collected with EsoCheck. Its other subsidiary, Veris Health Inc., is focused on enhanced personalized cancer care through remote patient monitoring using implantable vascular access port with wireless communication combined with an oncologist-designed remote digital healthcare platform.
Unternehmensinformationen
BörsenkürzelPAVM
Name des UnternehmensPAVmed Inc
IPO-datumJul 27, 2016
CEODr. Lishan Aklog, M.D.
Anzahl der mitarbeiter39
WertpapierartOrdinary Share
GeschäftsjahresendeJul 27
Addresse360 Madison Avenue
StadtNEW YORK
BörseNASDAQ Capital Market Consolidated
LandUnited States of America
Postleitzahl10017
Telefon12129494319
Websitehttps://pavmed.com/
BörsenkürzelPAVM
IPO-datumJul 27, 2016
CEODr. Lishan Aklog, M.D.
Führungskräfte
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Michael J. Glennon
Mr. Michael J. Glennon
Independent Vice Chairman of the Board
Independent Vice Chairman of the Board
81.67K
--
Dr. Lishan Aklog, M.D.
Dr. Lishan Aklog, M.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
78.72K
--
Mr. Ronald M. (Ron) Sparks
Mr. Ronald M. (Ron) Sparks
Independent Director
Independent Director
65.00K
--
Mr. Dennis M. Mcgrath
Mr. Dennis M. Mcgrath
President, Chief Financial Officer
President, Chief Financial Officer
50.83K
--
Mr. Sundeep Agrawal, M.D.
Mr. Sundeep Agrawal, M.D.
Director
Director
12.20K
--
Mr. Michael A. Gordon
Mr. Michael A. Gordon
General Counsel, Secretary
General Counsel, Secretary
--
--
Ms. Debra J. White
Ms. Debra J. White
Independent Director
Independent Director
--
--
Mr. Timothy (Tim) Baxter
Mr. Timothy (Tim) Baxter
Independent Director
Independent Director
--
--
Mr. Matt Riley
Mr. Matt Riley
Director of Investor Relations
Director of Investor Relations
--
--
Mr. Shaun M. O'Neil
Mr. Shaun M. O'Neil
Chief Operating Officer, Executive Vice President
Chief Operating Officer, Executive Vice President
--
--
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Michael J. Glennon
Mr. Michael J. Glennon
Independent Vice Chairman of the Board
Independent Vice Chairman of the Board
81.67K
--
Dr. Lishan Aklog, M.D.
Dr. Lishan Aklog, M.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
78.72K
--
Mr. Ronald M. (Ron) Sparks
Mr. Ronald M. (Ron) Sparks
Independent Director
Independent Director
65.00K
--
Mr. Dennis M. Mcgrath
Mr. Dennis M. Mcgrath
President, Chief Financial Officer
President, Chief Financial Officer
50.83K
--
Mr. Sundeep Agrawal, M.D.
Mr. Sundeep Agrawal, M.D.
Director
Director
12.20K
--
Mr. Michael A. Gordon
Mr. Michael A. Gordon
General Counsel, Secretary
General Counsel, Secretary
--
--
Umsatzaufteilung
Keine Daten
Keine Daten
Nach Geschäftsbereich
Nach Region
Keine Daten
Aktionärsstatistik
Aktualisiert: Fri, May 16
Aktualisiert: Fri, May 16
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
Tasso Partners, LLC
14.61%
First Manhattan Co. LLC
4.05%
Dubreville (Anthony Michael)
3.44%
Pavilion Venture Partners, L.L.C.
1.69%
Geode Capital Management, L.L.C.
0.53%
Other
75.68%
Aktionäre
Aktionäre
Anteil
Tasso Partners, LLC
14.61%
First Manhattan Co. LLC
4.05%
Dubreville (Anthony Michael)
3.44%
Pavilion Venture Partners, L.L.C.
1.69%
Geode Capital Management, L.L.C.
0.53%
Other
75.68%
Aktionärstypen
Aktionäre
Anteil
Corporation
16.31%
Individual Investor
5.92%
Investment Advisor
5.88%
Investment Advisor/Hedge Fund
0.72%
Hedge Fund
0.19%
Research Firm
0.14%
Venture Capital
0.13%
Other
70.72%
Institutionelle Beteiligung
Aktualisiert: Tue, Jul 1
Aktualisiert: Tue, Jul 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q2
101
5.16M
29.28%
+2.77M
2025Q1
106
5.16M
31.74%
+3.03M
2024Q4
110
2.41M
17.67%
+156.53K
2024Q3
120
2.58M
24.42%
+197.13K
2024Q2
133
1.94M
20.61%
-301.78K
2024Q1
169
2.19M
26.52%
+433.78K
2023Q4
185
1.60M
20.86%
-48.73K
2023Q3
208
1.30M
18.00%
-268.87K
2023Q2
221
1.26M
18.65%
-731.24K
2023Q1
227
1.31M
20.36%
-649.18K
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
Tasso Partners, LLC
2.57M
14.61%
+2.57M
--
Feb 21, 2025
First Manhattan Co. LLC
714.10K
4.05%
+14.10K
+2.01%
Mar 31, 2025
Dubreville (Anthony Michael)
606.26K
3.44%
+606.26K
--
Aug 30, 2024
Pavilion Venture Partners, L.L.C.
297.11K
1.69%
--
--
Apr 22, 2025
Geode Capital Management, L.L.C.
92.67K
0.53%
+13.20K
+16.62%
Mar 31, 2025
Glennon (Michael J)
81.67K
0.46%
+1.00
+0.00%
Apr 22, 2025
The Vanguard Group, Inc.
81.49K
0.46%
--
--
Mar 31, 2025
Aklog (Lishan)
78.72K
0.45%
--
--
Apr 22, 2025
BlackRock Institutional Trust Company, N.A.
72.66K
0.41%
--
--
Mar 31, 2025
CAPTRUST Financial Advisors
65.05K
0.37%
+65.05K
--
Mar 31, 2025
Mehr Anzeigen
Verbundene ETFs
Aktualisiert: Sat, Aug 2
Aktualisiert: Sat, Aug 2
Name
Anteil
iShares Core S&P Total U.S. Stock Market ETF
0%
iShares Core S&P Total U.S. Stock Market ETF
Anteil0%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Art
Verhältnis
Dec 04, 2023
Merger
15<1
Dec 04, 2023
Merger
15<1
Dec 04, 2023
Merger
15<1
Dec 04, 2023
Merger
15<1
Datum
Art
Verhältnis
Dec 04, 2023
Merger
15<1
Dec 04, 2023
Merger
15<1
Dec 04, 2023
Merger
15<1
Dec 04, 2023
Merger
15<1
